News and Trends 2 Apr 2020 Swiss and German Team to Develop Inhaled mRNA Coronavirus Treatment The Swiss antibody specialist Neurimmune and the German RNA biotech Ethris are collaborating to develop inhaled messenger RNA (mRNA) antibodies that can treat the catastrophic respiratory effects of coronavirus disease, also known as Covid-19. The therapeutic mRNA would be delivered directly into the lungs of symptomatic patients via nebulizers with nanoparticle aerosols. The mRNA could […] April 2, 2020 - 3 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2020 Themis and Institut Pasteur Join Coronavirus Vaccine Hunt The Austrian biotech Themis — specializing in vaccines for infectious and insect-borne diseases — has jumped on the coronavirus vaccine bandwagon along with the Institut Pasteur and other international partners. The collaboration will be led by the Parisian Institut Pasteur, whose vaccine technology — in this case modifying a measles virus vector to carry coronavirus […] March 20, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 7 Feb 2020 Sigrid Therapeutics Prevents Type 2 Diabetes Using Silica Powder in the Gut In Stockholm, Sweden, Sigrid Therapeutics is developing an ingestible silica powder that can treat type 2 diabetes and obesity without being absorbed in the gut. Mission: To produce the first prophylactic silica-based treatment for type 2 diabetes that does not enter the bloodstream. Some people have higher blood sugar levels than normal, but not high […] February 7, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 17 Jan 2020 This Biotech Is Developing a Pill to Rival Antibiotics in Vaginal Infections Gedea Biotech is nestled in the historic city of Lund, Sweden. The company is developing a pill that could tackle recurrent bacterial vaginosis infections without harming the vaginal microbiome like current antibiotics do. Mission: To develop a pill that can clear bacterial vaginosis by restoring normal acidity levels in the vagina, which helps good bacteria […] January 17, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2019 After Unexpected Setback, GenSight Seeks Approval for Blindness Gene Therapy The French biotech GenSight will apply for regulatory approval for its gene therapy despite the treatment unexpectedly resulting in the improvement of the eyes treated with a placebo in a phase III trial. GenSight is developing a gene therapy designed to treat progressive vision loss caused by the rare genetic condition Leber hereditary optic neuropathy. […] May 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 Mar 2019 Galapagos Nears First Drug Approval with Phase III Success in Rheumatoid Arthritis Galapagos has released positive data from two phase III trials testing its flagship drug candidate, filgotinib, that will let the company and its partner Gilead apply for marketing approval. 20 years after its foundation, Galapagos is finally approaching the finish line. Yesterday, the company has shared positive data from two clinical trials that together enrolled […] March 29, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Mar 2019 Update: Hansa Biopharma Applies for EMA Market Approval for Kidney Transplant Drug Update (01/03/2019): Hansa Biopharma (previously named Hansa Medical) has filed an application for marketing authorization for imlifidase with the EMA also for use in patients undergoing kidney transplants. Update (18/10/2018): Imlifidase has just been given Fast Track Designation by the FDA for application in transplantation. The designation should accelerate the treatment through the FDA’s regulatory process, with […] March 1, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2018 Watch Out Eli Lilly: Novo’s Diabetes Drug Ozempic Gets European Approval Update (13/02/2018): The European Commission has given Novo Nordisk a market authorization for Ozempic (semaglutide), bringing the competition for Eli Lilly’s Trulicity over to Europe. Eli Lilly executives have said that they are not worried by Novo’s competition, and keep confident on the performance of Trulicity, which now tops 40% of the market share of diabetes drugs belonging […] February 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2017 How to Deal with Regulations to Get Approval for CAR-T Cells The biotech industry is diving into the field of highly individualized gene and cell therapy products. The first CAR-T therapy has just been approved in the US and other breakthrough technologies like mRNA and CRISPR have a foot in the door. But getting to the market is not straightforward, not only for developers but also for […] December 20, 2017 - 8 minutesmins - By Timothé Cynober Share WhatsApp Twitter Linkedin Email
News and Trends 18 Dec 2017 Belgian Biotech’s Crohn’s Disease Cell Therapy Gets Recommended for Approval An EMA committee has supported an allogeneic stem cell therapy for the first time, as TiGenix’s Crohn’s disease candidate is backed for approval. TiGenix and its Japanese partner, Takeda, are developing a stem cell therapy for Crohn’s disease – an autoimmune disease affecting the gastrointestinal tract. This morning, the companies have revealed that their candidate, Cx601, has received the backing […] December 18, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2016 Curing Cancer with Safer Transplants: UK Approval to start Clinical Trials Kiadis Pharma has received approval to test in the UK an immune therapy to address the big challenges of bone marrow transplants, currently the only cure for blood cancers. Kiadis Pharma, based in Amsterdam, is working on therapies to improve the outcome of hematopoietic stem cell transplantation (HSCT), a common treatment for multiple types of […] December 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email